Author:
Chrienova Zofia,Rysanek David,Oleksak Patrik,Stary Dorota,Bajda Marek,Reinis Milan,Mikyskova Romana,Novotny Ondrej,Andrys Rudolf,Skarka Adam,Vasicova Pavla,Novak Josef,Valis Martin,Kuca Kamil,Hodny Zdenek,Nepovimova Eugenie
Abstract
To date, the most studied drug in anti-aging research is the mTOR inhibitor – rapamycin. Despite its almost perfect anti-aging profile, rapamycin exerts one significant limitation – inappropriate physicochemical properties. Therefore, we have decided to utilize virtual high-throughput screening and fragment-based design in search of novel mTOR inhibiting scaffolds with suitable physicochemical parameters. Seven lead compounds were selected from the list of obtained hits that were commercially available (4, 5, and 7) or their synthesis was feasible (1, 2, 3, and 6) and evaluated in vitro and subsequently in vivo. Of all these substances, only compound 3 demonstrated a significant cytotoxic, senolytic, and senomorphic effect on normal and cancerous cells. Further, it has been confirmed that compound 3 is a direct mTORC1 inhibitor. Last but not least, compound 3 was found to exhibit anti-SASP activity concurrently being relatively safe within the test of in vivo tolerability. All these outstanding results highlight compound 3 as a scaffold worthy of further investigation.
Funder
Grantová Agentura České Republiky
Univerzita Hradec Králové
Univerzita Karlova v Praze
Ministerstvo Zdravotnictví Ceské Republiky
Subject
Cognitive Neuroscience,Aging
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献